TABLE 1.
Characteristics of Patients with a Paclitaxel or Docetaxel Hypersensitivity Reaction Referred for Allergy Evaluation prior to COVID‐19 Vaccination.
| Characteristics | No. (%) | ||
|---|---|---|---|
| All (n = 21) | Paclitaxel allergy (n = 17) | Docetaxel allergy (n = 4) | |
| Age, mean (SD), year | 57 (10.5) | 58 (10.7) | 52 (8.6) |
| Female | 20 (95) | 17 (100) | 3 (75) |
| Race | |||
| White | 20 (95) | 17 (100) | 3 (75) |
| Asian | 1 (5) | 0 (0) | 1 (25) |
| History of atopy | 14 (67) | 12 (71) | 2 (50) |
| Anaphylaxis | 12 (57) | 11 (65) | 1 (25) |
| Allergic rhinitis | 5 (24) | 4 (24) | 1 (25) |
| Food allergy | 5 (24) | 4 (24) | 1 (25) |
| Asthma | 4 (19) | 3 (18) | 1 (25) |
| Atopic dermatitis | 1 (5) | 1 (6) | 0 (0) |
| Time since hypersensitivity reaction | |||
| Less than 1 year | 8 (38) | 6 (35) | 2 (50) |
| 1–4 years | 3 (14) | 3 (18) | 0 (0) |
| 5–9 years | 3 (14) | 2 (12) | 1 (25) |
| 10 or more years | 6 (29) | 6 (35) | 0 (0) |
| Unknown | 1 (5) | 0 (0) | 1 (25) |
| Hypersensitivity reaction symptoms a | |||
| Cutaneous | 18 (86) | 14 (82) | 4 (100) |
| Respiratory | 15 (71) | 12 (71) | 3 (75) |
| Gastrointestinal | 4 (19) | 2 (12) | 2 (50) |
| Cardiovascular | 2 (10) | 2 (12) | 0 (0) |
| Other | 8 (38) | 6 (35) | 2 (50) |
| Severity of reaction b | |||
| Grade 0 | 1 (5) | 1 (6) | 0 (0) |
| Grade 1 | 3 (14) | 2 (12) | 1 (25) |
| Grade 2 | 3 (14) | 2 (12) | 1 (25) |
| Grade 3 | 14 (67) | 12 (71) | 2 (50) |
| Management of chemotherapy hypersensitivity reaction | |||
| Antihistamines | 19 (90) | 16 (94) | 3 (75) |
| Corticosteroid | 14 (67) | 11 (65) | 3 (75) |
| Epinephrine | 1 (5) | 1 (6) | 0 (0) |
| Other c | 3 (14) | 2 (12) | 1 (25) |
| COVID−19 vaccine(s) received | |||
| mRNA (Pfizer‐BioNTech or Moderna) | 16 (76) d | 12 (71) e | 4 (100) f |
| Janssen | 5 (24) | 5 (29) | 0 (0) |
Cutaneous: hives, rash, itching, swelling (not throat), and flushing; respiratory: wheezing, chest tightness, shortness of breath, cough, and sensation of throat closing; gastrointestinal: gastrointestinal upset, abdominal cramping, diarrhea, vomiting, and nausea; cardiovascular: tachycardia and hypotension; other: 7 patients had back pain, 1 patient had lightheadedness, and 1 patient had sinus pressure.
Grading of reaction based on Ring and Messmer criteria. 7
One patient received acetaminophen and oxycodone, and 2 patients received unknown treatment.
Twelve patients received Pfizer‐BioNTech, and 4 patients received Moderna COVID‐19 vaccine.
Nine patients received Pfizer‐BioNTech, and 3 patients received Moderna COVID‐19 vaccine.
Three patients received Pfizer‐BioNTech, and 1 patient received Moderna COVID‐19 vaccine.